Michael E Weinblatt
Overview
Explore the profile of Michael E Weinblatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
223
Citations
15555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weinblatt M, Taylor P, McInnes I, Atsumi T, Strand V, Takeuchi T, et al.
BMJ Open
. 2025 Mar;
15(3):e088869.
PMID: 40044198
Objectives: To investigate the long-term safety and efficacy of otilimab, an antigranulocyte-macrophage colony-stimulating factor monoclonal antibody, for patients with rheumatoid arthritis (RA). Methods: ContRAst X (NCT04333147) was a phase 3,...
2.
Amaral J, Schoen R, Weinblatt M, Candido E
Trop Med Infect Dis
. 2025 Feb;
10(2).
PMID: 39998058
Chikungunya fever (CHIKF) is a re-emerging infectious disease caused by the chikungunya virus (CHIKV), transmitted primarily by Aedes mosquitoes. A significant number progress to chronic chikungunya arthritis, which shares similarities...
3.
Longley M, Gaffney R, Smith J, DeSimone M, Weinblatt M, Merola J
JAAD Case Rep
. 2025 Jan;
53():71-74.
PMID: 39823052
No abstract available.
4.
Botson J, Obermeyer K, LaMoreaux B, Padnick-Silver L, Verma S, Weinblatt M, et al.
Rheumatol Adv Pract
. 2024 Dec;
8(4):rkae145.
PMID: 39678124
Objectives: Pegloticase lowers serum urate (SU) but is limited by anti-drug antibodies. Methotrexate (MTX) co-administration increases urate-lowering response rate and decreases infusion reaction risk. This is of importance in uncontrolled...
5.
McDermott G, Hayashi K, Juge P, Gill R, Byrne S, Gagne S, et al.
Arthritis Care Res (Hoboken)
. 2024 Sep;
77(2):185-194.
PMID: 39257341
Objective: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) includes multiple subtypes with varying histopathology, prognosis, and potential treatments. Limited research has investigated risk factors for different RA-ILD subtypes. Therefore, we examined...
6.
Venkat R, Hayashi K, Juge P, McDermott G, Paudel M, Wang X, et al.
Clin Rheumatol
. 2024 Jun;
43(8):2453-2466.
PMID: 38898318
We aimed to determine the prevalence and outcomes for forced vital capacity percent predicted (FVCpp) decline among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We identified patients with RA-ILD...
7.
Weber B, Weisenfeld D, Jeffway M, Liu F, McDermott G, Coblyn J, et al.
J Rheumatol
. 2024 Jun;
51(9):942-944.
PMID: 38879189
No abstract available.
8.
Paudel M, Li R, Naik C, Shadick N, Weinblatt M, Solomon D
Rheumatology (Oxford)
. 2024 Jun;
64(3):1102-1110.
PMID: 38837701
Objectives: An estimated 5-20% of patients with rheumatoid arthritis (RA) fail multiple treatments and are considered 'difficult-to-treat' (D2T), posing a substantial clinical challenge for rheumatologists. A European League Against Rheumatism...
9.
Weber B, Weisenfeld D, Massarotti E, Seyok T, Cremone G, Lam E, et al.
J Am Heart Assoc
. 2024 Apr;
13(9):e030387.
PMID: 38686879
Background: Coronary microvascular dysfunction as measured by myocardial flow reserve (MFR) is associated with increased cardiovascular risk in rheumatoid arthritis (RA). The objective of this study was to determine the...
10.
McDermott G, DiIorio M, Kawano Y, Jeffway M, MacVicar M, Dahal K, et al.
Semin Arthritis Rheum
. 2024 Mar;
66:152421.
PMID: 38457949
Objective: Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was...